Journal article
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
Abstract
The aims of this study were reviewing our experience regarding the pulmonary toxicity of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus, discussing potential pathogenic mechanisms and proposing management strategies. Medical records and radiological reports of 22 patients treated with weekly doses of temsirolimus 25 mg were reviewed. Eight (36%) out of 22 patients developed pulmonary abnormalities compatible with drug-induced …
Authors
Duran I; Siu LL; Oza AM; Chung T-B; Sturgeon J; Townsley CA; Pond GR; Seymour L; Niroumand M
Journal
European Journal of Cancer, Vol. 42, No. 12, pp. 1875–1880
Publisher
Elsevier
Publication Date
August 2006
DOI
10.1016/j.ejca.2006.03.015
ISSN
0959-8049